Human medicines European public assessment report (EPAR): Pomalidomide Viatris, pomalidomide, Status: Opinion
Pomalidomide Viatris will be available as 1 mg, 2 mg, 3 mg and 4 mg hard capsules.
- Pomalidomide Viatris will be available as 1 mg, 2 mg, 3 mg and 4 mg hard capsules.
- Pomalidomide Viatris is a generic of Imnovid, which has been authorised in the EU since 05 August 2013.
- Studies have demonstrated the satisfactory quality of Pomalidomide Viatris and its bioequivalence to the reference product Imnovid.
- Treatment with Pomalidomide Viatris should be carried out under the supervision of physicians experienced in the treatment of multiple myeloma.